What is Ixaltis?
IXALTIS, SA is a specialized biopharmaceutical company focused on genitourinary and kidney diseases. With a capital of 538,784, the company is dedicated to the experimental research and development of novel therapeutic compounds. A key asset is Litoxetine (IXA-001), acquired under exclusive license from Sanofi. Early pre-clinical trials, conducted by both private and academic institutions, have demonstrated promising results in treating urinary incontinence, a condition affecting approximately 400 million individuals globally, with a notable prevalence in women over 50.
How much funding has Ixaltis raised?
Ixaltis has raised a total of $8.9M across 1 funding round:
Private Equity
$8.9M
Private Equity (2016): $8.9M, investors not publicly disclosed
What's next for Ixaltis?
The substantial enterprise-level funding and major strategic investment signal Ixaltis's readiness to scale its operations and accelerate the clinical development of its promising drug candidates, particularly Litoxetine. This capital infusion is expected to fuel further pre-clinical and potentially clinical trials, aiming to validate the efficacy of IXA-001 in addressing the significant unmet need in urinary incontinence. The company's strategic focus on niche but prevalent conditions positions it for substantial growth and potential market leadership in urological therapeutics.
See full Ixaltis company page
